NASDAQ: WGSGenedx Holdings Corp Stock
$89.74+4.47 (+5.24%)
Updated Sep 14, 2026
WGS Price
$89.74
Fair Value Price
N/A
Market Cap
$2.68B
52 Week Low
$32.21
52 Week High
$170.87
P/E
-24.65x
P/B
10.96x
P/S
8.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$454.43M
Earnings
-$106.36M
Gross Margin
69.4%
Operating Margin
-22.73%
Profit Margin
-23.4%
Debt to Equity
0.97
Operating Cash Flow
-$49M
Beta
1.89
Next Earnings
Oct 27, 2026
Ex-Dividend
N/A
Next Dividend
N/A
WGS Overview
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine WGS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
WGS
Ranked#29 of 40
Ranked#29 of 40
Be the first to know about important WGS news, forecast changes, insider trades & much more!
WGS News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how WGS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WGS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
WGS is poor value based on its book value relative to its share price (10.96x), compared to the US Health Information Services industry average (3.83x)
P/B vs Industry Valuation
WGS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more WGS due diligence checks available for Premium users.
Valuation
WGS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-24.65x
Industry
9.64x
Market
43.6x
WGS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.96x
Industry
3.83x
WGS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WGS's financial health
Profit margin
Revenue
$114.4M
Net Income
-$17.7M
Profit Margin
-15.5%
WGS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
WGS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$481.5M
Liabilities
$237.3M
Debt to equity
0.97
WGS's short-term assets ($246.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WGS's short-term assets ($246.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WGS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WGS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.0M
Investing
-$5.6M
Financing
$1.0M
WGS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
WGS vs Health Information Service Stocks
Genedx Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.